RCS - Eco Animal Health Gp - Trademark Approval for ECOVAXXIN® family in the EU

ECO Animal HealthAnnouncement

06/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240206:nRSF0924Ca&default-theme=true

RNS Number : 0924C  Eco Animal Health Group PLC  06 February 2024

06 February 2024

 

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Trademark Approval for ECOVAXXIN® family in the EU

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, is pleased to announce that the ECOVAXXIN®
trademark has been approved by the European Union ("EU").

In addition to this EU trademark ECOVAXXIN® has also been registered in the
USA and in the UK, giving extensive protection in key markets for animal
health products.

The registration for ECOVAXXIN® provides trademark branding for a family of
vaccine products. ECOVAXXIN® is a master trademark and will protect all ECO's
forthcoming vaccine products. Starting in 2025, the Company plans to market
its vaccine products in multiple jurisdictions, with multiple planned launches
over the next ten year period.

The first two planned products to carry the trademark will be the Company's
poultry mycoplasma vaccines, specifically ECOVAXXIN® MS, a vaccine against
Mycoplasma Synoviae, and ECOVAXXIN® MG, a vaccine against Mycoplasma
Gallisepticum.

The trademark approval supports ECO's strategy of accelerating growth through
the Company's research and development pipeline. The addition of new vaccines
is expected to significantly support sales and profit growth over the next ten
years.

David Hallas, Chief Executive Officer of ECO Animal Health Group plc,
commented: "This trademark approval, complemented by registrations in the USA
and the UK, provides broad protection for the ECOVAXXIN® family, fortifying
our commitment to advancing growth through innovative vaccine products and
supporting our strategic focus on R&D-driven expansion at ECO Animal
Health Group plc."

-Ends-

For further information please contact:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher
 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska
 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans
 ICR Consilium (Financial PR)                                   020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@consilium-comms.com

 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

( )

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATAMLTMTIMBAI